PDCD1 and head and neck squamous cell carcinoma: This may be related to the approval in 2016 of the anti-programmed death-1 (PD-1) immune checkpoint inhibitors nivolumab and pembrolizumab for the treatment of HNSCC patients with relapse or metastasis during or after platinum-containing chemotherapy (5).